<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122556">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01507142</url>
  </required_header>
  <id_info>
    <org_study_id>GAIA-AIDS-001</org_study_id>
    <nct_id>NCT01507142</nct_id>
  </id_info>
  <brief_title>Rapid Oral Test for Therapeutic Response in HIV/AIDS Patients</brief_title>
  <official_title>Rapid Oral Test for Therapeutic Response in HIV/AIDS Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gaia Medical Institute</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AIDS Healthcare Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gaia Medical Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study has been designed to evaluate a new oral test for therapeutic monitoring of
      HIV/AIDS patients that are receiving the combination Anti-Retroviral Therapy (cART). The
      test will measure saliva-based Stress Response Profiling(SRP) biomarkers using laboratory
      assays. Results of the test will show if HIV/AIDS patients successfully responded to cART.
      Preliminary studies showed that SRP biomarkers were strongly increased in cART-unresponsive
      AIDS patients. However, the diagnostic accuracy of the oral test, patients will be recruited
      to donate saliva: AIDS patients responsive or unresponsive to cART, and controls (acute or
      early HIV patients, and HIV-negative patients with hepatitis).

      The saliva samples will be used to measure SRP biomarker concentrations. Results will show
      whether the biomarker measurements provide accurate and specific diagnostics for ART
      response.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <primary_completion_date type="Anticipated">September 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>AIDS/HIV PROBLEM</condition>
  <arm_group>
    <arm_group_label>cART-unresponsive AIDS</arm_group_label>
    <description>HIV-positive, AIDS diagnosis, cART for &gt;18 months, &lt;200 CD4 Tcells/mm3 and Viral Load &gt;5000 copies/ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cART-responsive AIDS</arm_group_label>
    <description>HIV-positive, AIDS diagnosis, cART for &gt;18 months, &gt;350 CD4 Tcells/mm3 and Viral Load&lt;50 copies/ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Acute or early HIV infection</arm_group_label>
    <description>Acute HIV: Acute retroviral syndrome, Negative or positive HIV antibody, Positive HIV p24gag, viral load or NAAT / Early HIV: HIV antibody and viral load positive currently, negative in last 12 months, No clinical or immunological evidence of advanced HIV disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV-negative Hepatitis B</arm_group_label>
    <description>Negative HIV antibody and viral load, Positive HBV antibody, Positive or Negative HBV surface antigen, Negative or Positive HBV viral load</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Saliva
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV-positive, or HIV-negative and Hepatitis-positive adult participants
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Group 1, cART-unresponsive

          -  Documented HIV-positive before obtaining AIDS diagnosis

          -  cART for 18 months or longer

          -  consistent lab tests in previous 3-6 months: &lt; or equal to 200 CD4 T cells/mm3, viral
             load &gt;5000 HIV RNA copies/ml

        Group 2, cART-responsive

          -  Documented HIV-positive before obtaining AIDS diagnosis

          -  cART for 18 months or longer

          -  consistent lab tests in previous 3-6 months: &gt; or equal to 350 CD4 T cells/mm3, viral
             load &lt; or equal to 50 HIV RNA copies/ml

        Group 3, acute/early HIV

        Acute HIV:

          -  Signs and symptoms of acute retroviral syndrome in a person with either a negative or
             evolving antibody response (western blot or ELISA) in presence of a positive HIV
             p24gag antigen or HIV-1 proviral DNA PCR or positive HIV-1 RNA

        Early HIV:

          -  A positive antibody response (western blot or ELISA) with a documented negative
             serological test or plasma HIV-1 RNA within the past 12 months or a positive ELISA
             and a negative de-tuned ELISA within 30 days of a positive ELISA specimen in an
             untreated person with no clinical or immunological evidence of advanced HIV disease
             (CD4 count &gt;200 cells/mm3 or &gt;14%)

        Group 4, HIV-negative Hepatitis-positive

          -  HIV test negative (western blot, ELISA or viral load)

          -  Positive Hepatitis B surface antigen and detectable hepatitis B viral load (HCV B
             RNA), treated or not OR Positive Hepatitis C antibodies and detectable hepatitis C
             viral load (HCV C RNA), treated or not

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Non-adherent patients

          -  Any conditions which will affect saliva production: e.g. Sjogren's syndrome or
             chronic mouth dryness

          -  Cytotoxic chemotherapy, interferon treatment, or radiation therapy within the
             preceding 3 weeks

          -  Active alcohol or substance abuse (narcotics or other controlled substances) within 6
             months prior to the saliva sampling

          -  Significant psychiatric illness that in the opinion of the principle investigator
             might interfere with making an informed decision

          -  Incapable to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wayne Chen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>AIDS Healthcare Foundation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sarka Southern, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gaia Medical Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gerald Ramirez</last_name>
    <email>gerald.ramirez@aidshealth.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>AIDS Healthcare Foundation</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerald Ramirez</last_name>
      <phone>323-662-0492</phone>
      <phone_ext>15406</phone_ext>
      <email>gerald.ramirez@aidshealth.org</email>
    </contact>
    <investigator>
      <last_name>Wayne Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <lastchanged_date>July 16, 2012</lastchanged_date>
  <firstreceived_date>January 6, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>saliva</keyword>
  <keyword>diagnostics</keyword>
  <keyword>HIV</keyword>
  <keyword>AIDS</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
